DDW’s Megan Thomas reflects on the impact of AbbVie’s failed schizophrenia trials. Earlier this month, AbbVie provided updates confirming that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, have failed in the clinic1. AbbVie acquired Cerevel […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!